Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ZNH
|
|||
| Former ID |
DIB006495
|
|||
| Drug Name |
IDAZOXAN HYDROCHLORIDE
|
|||
| Synonyms |
IDAZOXAN HYDROCHLORIDE; 79944-56-2; Idazoxan HCl; RX 781094; MLS000069708; SMR000058458; SR-01000000206; Opera_ID_847; Idazoxan (hydrochloride); AC1L4CEL; MLS001148081; SCHEMBL707367; CHEMBL543467; CTK8G0263; MolPort-003-941-824; MYUBYOVCLMEAOH-UHFFFAOYSA-N; (+/-)-Idazoxan Monohydrochloride; Pharmakon1600-01506073; HMS1570J14; Tox21_500652; NSC759867; MFCD00069293; BN0267; AKOS024458652; NSC-759867; RX 781094A; LP00652; CCG-214002; 1H-Imidazole, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-,monohydrochloride; 1H-Imidazole, 2-(2,3-d
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neurological disorder [ICD-11: 6B60] | Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H13ClN2O2
|
|||
| Canonical SMILES |
C1CN=C(N1)C2COC3=CC=CC=C3O2.Cl
|
|||
| InChI |
1S/C11H12N2O2.ClH/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11;/h1-4,10H,5-7H2,(H,12,13);1H
|
|||
| InChIKey |
MYUBYOVCLMEAOH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 79944-56-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855744, 10252163, 12013061, 15196433, 17405213, 24278493, 46230606, 49979459, 50106461, 50106462, 53777758, 56422421, 57348005, 80422800, 91704604, 92125798, 92304251, 103674322, 103913614, 104438906, 135108885, 135113275, 135697892, 144076197, 162226966, 163135164, 163564606, 164814671, 170485588, 175611453, 179148916, 223961152, 226998321, 241139428, 241181899, 241377485, 252350840
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Modulator | [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00294944) The Effectiveness of Idazoxan in Treating TRD. U.S. National Institutes of Health. | |||
| REF 2 | Different sites of action for alpha 2-adrenoceptor antagonists in the modulation of noradrenaline release and contraction response in the vas deferens of the rat. J Pharm Pharmacol. 1992 Mar;44(3):231-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.